Department of Laboratory Medicine (Laboratory Hematology) , Kawasaki Medical School

ƒ2019`„

Sakakibara K, Tsujioka T, Kida JI, Kurozumi N, Nakahara T, Suemori SI, Kitanaka A, Arao Y, Tohyama K: Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway. Int J Hematol, in press. (doi: 10.1007/s12185-019-02667-1)

Murakami Y, Kimura Y, Kawahara A, Mitsuyasu S, Miyake H, Tohyama K, Endo Y, Yoshida N, Imamura Y, Watari K, Ono M, Okamura T, Kuwano M: The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes.Oncotarget 10(23):2270-2281, 2019. (doi: 10.18632/oncotarget.26784)

ƒ2018„

Morita H, Matsuoka A, Kida JI, Tabata H, Tohyama K, Tohyama Y: KIF20A, highly expressed in immature hematopoietic cells, supports the growth of HL60 cell line. Int J Hematol 108: 607-614, 2018. (doi: 10.1007/s12185-018-2527-y)

Matsuda A, Kawabata H, Tohyama K, Maeda T, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Usuki K, Chiba S, Ishikawa T, Arima N, Nohgawa M, Ohta A, Miyazaki Y, Nakao S, Ozawa K, Arai S, Kurokawa M, Mitani K, Takaori-Kondo A; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes: Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study.Leuk Res 74: 137-143, 2018. (doi:10.1016/j.leukres.2018.06.003)

Sun J, He X, Zhu Y, Ding Z, Dong H, Feng Y, Du J, Wang H, Wu X, Zhang L, Yu X, Lin A, McDonald T, Zhao D, Wu H, Hua WK, Zhang B, Feng L, Tohyama K, Bhatia R, Oberdoerffer P, Chung YJ, Aplan PD, Boultwood J, Pellagatti A, Khaled S, Kortylewski M, Pichiorri F, Kuo YH, Carlesso N, Marcucci G, Jin H, Li L: SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. Cell Stem Cell 23: 355-369, 2018.

Kida J, Tsujioka T, Suemori S, Okamoto S, Sakakibara K, Takahata T, Yamauchi T, Kitanaka A, Tohyama Y, Tohyama K: An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS.Leukemia, 32: 1846-1850, 2018.

Nakahara T, Suemori S, Tsujioka T, Kataoka M, Kataoka H, Shibakura M, Tohyama K : Utility of a Fluorescence Microscopy Imaging System for Analyzing the DNA Ploidy of Pathological Megakaryocytes Including 5q- Syndrome.Acta Medica Okayama, 72: 249-256, 2018.

Tohyama K: Present status and perspective of laboratory hematology in Japan: On the standardization of blood cell morphology including myelodysplasia: On behalf of the Japanese Society for Laboratory Hematology. Int J Lab Hematol,40(Suppl 1): 120-125, 2018.

ƒ2017„

Oben@KZ, Alhakeem SS , McKenna MK, Brandon JA, Mani R, Noothi SK, Jinpeng L, Akunuru S, Dhar SK, Singh IP, Liang Y, Wang C, Abdel-Latif A, Stills Jr HF, St. Clair DK, Geiger H, Muthusamy N, Tohyama K, Gupta RC, Bondada S : Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by withaferin-A. Oncotarget 8: 77436-77452, 2017.

Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M; for National Research Group on Idiopathic Bone Marrow Failure Syndromes: A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). Am J Hematol 92: 1324-1332, 2017.

Kawabata H, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Zaike Y, Usuki K, Chiba S, Ishikawa T, Arima N, Nogawa M, Ohta A, Miyazaki Y, Mitani K, Ozawa K, Arai S, Kurokawa M, Takaori-Kondo A : Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes: Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. Int J Hematol 106: 375-384, 2017.

Li L, Sheng Y, Li W, Hu C, Mittal N, Tohyama K, Seba A, Zhao YY, Ozer H, Zhu T, Qian Z : Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes:ƒΐ-catenin is a candidate therapeutic target for myeloid neoplasms with del(5q). Cancer Res 77: 4116-4126, 2017.

Sekine M, Kubuki Y, Kameda T, Takeuchi M, Toyama T, Kawano N, Maeda K, Sato S, Ishizaki J, Kawano H, Kamiunten A, Akizuki K, Tahira Y, Shimoda H, Shide K, Hidaka T, Kitanaka A, Yamashita K, Matsuoka H, Shimoda K : Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice. European journal of haematology 98(5): 501-507, 2017.

Kubuki Y, Yamaji T, Hidaka T, Kameda T, Shide K, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Kitanaka A, Shimoda K: TET2 mutation in diffuse large B-cell lymphoma. Journal of clinical and experimental hematopathology 56(3): 145-149, 2017.

Shimosaki S, Nakahata S, Ichikawa T, Kitanaka A, Kameda T, Hidaka T, Kubuki Y, Kurosawa G, Zhang L, Sudo Y, Shimoda K, Morishita K : Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma. Biochemical and biophysical research communications 485(1): 144-151, 2017.

Kubuki Y, Shide K, Kameda T, Yamaji T, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hashimoto K, Yamamoto S, Hasuike S, Hidaka T, Nagata K, Kitanaka A, Shimoda K : Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.Annals of laboratory medicine (2): 159-161, 2017.

ƒ2016„

Okamoto S, Tsujioka T, Suemori S, Kida J, Kondo T, Tohyama Y, Tohyama K: Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression. Cancer Sci 107: 1302-1314, 2016.

Kondo T, Tasaka T, Tomioka N, Sano F, Tokunaga H, Suemori S, Tsujioka T, Matsuhashi Y, Nakanishi H, Wada H, Tohyama K, Sugihara T: Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasms. Springerplus 5: e1146, 2016.

Kobayashi S, Ueda Y, Nannya Y, Shibayama H, Tamura H, Ogata K, Akatsuka Y, Usuki K, Ito Y, Okada M, Suzuki T, Hata T, Matsuda A, Tohyama K, Kakumoto K, Koga D, Mitani K, Naoe T, Sugiyama H, Takaku F: Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Cancer Biomark 17: 21-32, 2016.

Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S: Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534(7607): 402-406, 2016.

Kitanaka A, Takenaka K, Shide K, Miyamoto T, Kondo T, Ozawa K, Kurokawa M, Akashi K, Shimoda K: Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients. International journal of hematology 103(4): 423-428, 2016.

ƒ2015„

Tsujioka T, Yokoi A, Itano Y, Takahashi K, Ouchida M, Okamoto S, Kondo T, Suemori S, Tohyama Y, Tohyama K: Five-aza-2f-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells. Sci Rep 5: e16709, 2015.

Matsumoto H, Okumura H, Murakami H, Kubota H, Higashida M, Tsuruta A, Tohyama K, Hirai T: Fluctuation in plasma 5-fluorouracil concentration during continuous 5-fluorouracil infusion for colorectal cancer.Anticancer Res 35: 6193-6199, 2015.

Suemori S, Wada H, Nakanishi H, Tsujioka T, Sugihara T, Tohyama K: Analysis of hereditary elliptocytosis with decreased binding of eosin-5-maleimide to red blood cells. BioMed Res Int (Special Issue on gPhylogeny and Ontogeny of Erythropoiesish), Vol 2015, Article ID 451861 (e1-6), 2015.

Hyoda T, Tsujioka T, Nakahara T, Suemori S, Okamoto S, Kataoka M, Tohyama K: Rigosertib induces cell death of an MDS-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci 106: 287-293, 2015.

ƒ2014„

Hayashi K, Tasaka T, Hirose T, Furukawa S, Kohguchi K, Matsuhashi Y, Wada H, Tohyama K, Sugihara T: Delayed false elevation of circulating tacrolimus concentrations after cord blood transplantation in a patient with myelodysplastic syndrome. Intern Med 53: 2635-2638, 2014.

Hu X-M, Yuan B, Tanaka S, Song M-M, Onda K, Tohyama K, Zhou A-X, Toyoda H, Hirano T: Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines. Hematology, 19: 352-360, 2014.

Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT: An MDS xenograft model utilizing a patient-derived cell line. Leukemia 28: 1142-1145, 2014.

Kawakami T, He J, Morita H, Yokoyama K, Kaji H, Tanaka C, Suemori S, Tohyama K, Tohyama Y: Rab27a is essential for the formation of neutrophil extracellular traps (NETs) in neutrophil-like differentiated HL60 cells. PLoS One 9: e84704, 2014.

ƒ2013„

Tsujioka T, Yokoi A, Uesugi A, Kishimoto M, Tochigi A, Suemori S, Tohyama Y, Tohyama K: Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines. Exp Hematol 41: 189-197, 2013.

Ueda Y, Mizutani C, Nannya Y, Kurokawa M, Kobayashi S, Takeuchi J, Tamura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Niimi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Ogawa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F: Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Leuk Lymphoma 54: 1450-1458, 2013.

Nagase S, Kohguchi K, Tohyama K, Watanabe M, Iwatani Y: Interference by pralidoxime (PAM) salts in clinical laboratory tests. Clin Chim Acta 416: 72-79, 2013.

ƒ2012„

Imashuku S, Kudo N, Kubo K, Saigo K, Okuno N, Tohyama K: Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation. J Blood Med 3: 157-61, 2012.

Ogata K, Kakumoto K, Matsuda A, Tohyama K, Tamura H, Ueda Y, Kurokawa M, Takeuchi J, Shibayama H, Emi N, Motoji T, Miyazaki Y, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F: Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: A multicenter validation study. Leuk Res 36: 1229-1236, 2012.

Oki Y, Kondo Y, Yamamoto K, Ogura M, Kasai M, Kobayashi Y, Watanabe T, Uike N, Ohyashiki K, Okamoto S, Ohnishi K, Tomita A, Miyazaki Y, Tohyama K, Mukai HY, Hotta T, Tomonaga M: Phase I/II study of decitabine in patients with myelodysplastic syndrome: A multi-center study in Japan. Cancer Sci 103: 1839-1847, 2012.

Imashuku S, Kudo N, Kubo K, Takahashi N, Tohyama K: Persistent thrombocytosis in elderly patients with rare hyposplenias that mimic essential thrombocythemia. Int J Hematol 95: 702-705, 2012.

Yoshida A, Zokumasu K, Wano Y, Yamauchi T, Imamura S, Takagi K, Kishi S, Urasaki Y, Tohyama K, Ueda T: Marked upregulation of Survivin and Aurora-B kinase are associated with disease progression in the myelodysplastic syndromes. Haematologica 97: 1372-1379, 2012.

Tohyama K : Editorial (as the Executive Guest Editor): New treatment strategy of the myelodysplastic syndromes. Curr Pharm Design 18: 3147-3148, 2012.

Tohyama K: Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes. Curr Pharm Design 18: 3190-3197, 2012.

Tsujioka T, Matsuoka A, Tohyama Y, Tohyama K: Approach to new therapeutics: Investigation by the use of MDS-derived cell lines. Curr Pharm Design 18: 3204-3214, 2012.

Matsuda A, Taniwaki M, Jinnai I, Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Tohyama K, Takatoku M, Ozawa K: Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study. Leuk Res 36: 575-580, 2012.

Tanaka C, Kaji H, He J, Hazama R, Yokoyama K, Kinoshita E, Tsujioka T, Tohyama K, Yamamura H, Nishio H, Tohyama Y: Rab27b regulates c-kit expression by controling the secretion of stem cell factor. Biochem Biophys Res Comm 419: 368-373, 2012.

ƒ2011„

Matsuda K, Suzuki K, Ishihara S, Morinaga M, Okamoto M, Shiino Y, Horiuchi I, Tohyama K, Ichihara K: Assessment of the severity of organophosphate (fenitrothion) poisoning based on its serum concentration and clinical parameters. Clin Toxicol 49: 820-827, 2011.

Inaba T, Yuki Y, Yuasa S, Fujita N, Yoshitomi K, Kamisako T, Torii K, Okada T, Urasaki Y, Ueda T, Tohyama K: Clinical utility of the neutrophil distribution pattern obtained using the CELL-DYN SAPPHIRE hematology analyzer for the diagnosis of myelodysplastic syndrome. Int J Hematol 94: 169-77, 2011.

Tasaka T, Tohyama K,Ohyashiki K, Ozawa K: 5q- syndrome in Japan. Int J Hematol 93: 827-829, 2011.

Tsujioka T, Tohyama K : Application of laser scanning cytometry to clinical and laboratory hematology. in :Laser Scanning, Theory and Applications (edited by Wang CC), pp185-194, InTech, Rijeka, Croatia, 2011.

Yokoyama K, Kaji H, He J, Tanaka C, Hazama R, Kamigaki T, Ku Y, Tohyama K, Yumi Tohyama: Rab27a negatively regulates phagocytosis by prolongation of the actin-coating stage around phagosomes. J Biol Chem 286: 5375-5382, 2011.

Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J, Kuchenbauer F, Hirst M, Tohyama K, Humphries RK, Lam RL, Marra M, Karsan A: Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 117: 595-607, 2011.

Tsujioka T, Kishimoto M, Kondo T, Matsuoka A, Tasaka T, Sugihara T, Wada H and ,Tohyama K: Impact of serum soluble interleukin-2 receptor levels on the diagnosis of malignant lymphoma. Kawsaki Medical Journal 37(1): 19-27, 2011.

Inoue T, Tashiro Y, Takeuchi M, Otani T, Tsuji-Takayama K, Okochi A, Mukae Y, Koreishi M, Yamasaki F, Kumon H, Nakamura S, Kibata M, Kondo E : Potent anti-tumor killing activity of the multifunctional Treg cell line HOZOT against human tumors with diverse origins. Int J Oncol 38(5): 1299-306, 2011.

ƒ2010„

Matsuoka A, Tochigi A, Kishimoto M, Nakahara T, Kondo T,Tsujioka T, Tasaka T, Tohyama Y, Tohyama K: Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia 24: 748-755, 2010.

Akiyama N, Miyazawa K, Kanda Y, Tohyama K, Omine M, Mitani K, Ohyashiki K: Multicenter phase II trial of vitamin K2 monotherapy and vitamin K2 plus 1ƒΏ-hydroxyvitamin D3 combination therapy for low-risk myelodysplastic syndromes. Leuk Res 34: 1151-1157, 2010.

Tamura H, Dan K, Yokose N, Iwakiri R, Ohta M, Sakamaki H, Tohyama K, Kondo A, Hyodo H, Nakamura K, Yamashita T, Elisseeva OA, Oka Y, Oji Y, Sugiyama H, Ogata KFPrognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheralblood in patients with myelodysplastic syndromes. Leuk Res 34: 986-990,2010.

Kubo Y, Kakazu N, Tasaka T, Oka D, Hirose T, Matsuhashi Y, Wada H, Tohyama K, Sugihara T: Acute lymphocytic leukemia(ALL) with t(8;14)(q11.2;q32) in an elderly patient. Leuk Res 34: e82-e84, 2010.

ƒ2009„

Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y,Kimura A, Tsudo M, Matsuda A, Tohyama K, Taniwaki M, Takeshita K, Takatoku M,Ozawa K: Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes (MDS) with a deletion 5q abnormality. Int J Hematol 90: 353-360, 2009.

Kondo T, Tasaka T, Sano F, Matsuda K, Kubo Y, Matsuhashi Y, Nakanishi H, Sadahira Y, Wada H, Sugihara H, Tohyama K: Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts. Leuk Res 33: e137-138, 2009.

Hazama R, Qu X, Yokoyama K, Tanaka C, Kinoshita E, He J, Takahashi S, Tohyama K, Yamamura H, Tohyama Y: ATP-induced osteoclast function; the formation of sealing-zone like structure and the secretion of lytic granules via microtubule-deacetylation under the control of Syk. Genes to Cells 14: 871-884, 2009.

Mannouji K, Tasaka T, Akiyama T, Irei I, Sano F, Matsuhashi Y, Wada H, Tohyama K, Sugihara T, Sadahira Y: Transformation from follicular lymphoma to high-grade B-cell lymphoma/leukemia with additional t(2;8)(p12;q24), with inverse expressions of c-MYC and BCL-2, and light-chain switch. Pathol Internatl 59: 261-264, 2009.

Nishikawa Y, Sato H, Oka T, Yoshino T, Takahashi K: Immunohistochemical discrimination of plasmacytoid dendritic cells from myeloid dendritic cells in human pathological tissues. J Clin Exp Hematop 49: 23-31, 2009.

Sato Y, Kojima M, Takata K, Morito T, Asaoku H, Takeuchi T, Mizobuchi K, Fujihara M, Kuraoka K, Nakai T, Ichimura K, Tanaka T, Tamura M, Nishikawa Y, Yoshino T: Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease. Mod Pathol 22: 589-99, 2009.

ƒ2008„

Tasaka T, Tohyama K, Kishimoto M, Ohyashiki K, Mitani K, Hotta T, Kanamaru A, Okamoto S, Karasawa M, Kimura A, Tomonaga M, Uchiyama T, Ozawa K: Myelodysplastic syndrome (MDS) with chromosome 5 abnormalities : a nation-wide survey in Japan. Leukemia 22: 1874-1881, 2008.

Kondo T, Okuno N, Naruse H, Kishimoto M, Tasaka T, Tsujioka T, Matsuoka A, Sugihara T, Tohyama Y, Tohyama K: Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm. Leuk Lymphoma 49: 1784-1791, 2008.

Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A, Spinelli JJ, Eaves CJ, Eaves AC, Horsman DE, Lam WL, Karsan A: High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 112: 3412-3424, 2008.

Higa T, Tasaka T, Kubo Y, Nakagiri I, Sano F, Matsuhashi Y, Fukai Y, Wada H, Tohyama K, Sugihara T: Successful treatment of meningoencephalitis caused by methicillin-resistant Staphylococcus aureus with intravenous linezolid in an allogeneic cord blood stem cell transplant recipient. Scand J Infect Dis, 40: 990-992, 2008.

Tsujioka T, Tochigi A, Kishimoto M, Kondo T, Tasaka T, Wada H, Sugihara T, Tohyama K: DNA ploidy and cell cycle analysis in the bone marrow cells of the patients with megaloblastic anemia using a laser scanning cytometry. Cytometry B (Clin Cytometry) 74: 104-109, 2008.

Wakimoto T, Tomisaka R, Nishikawa Y, Sato H, Yoshino T, Takahashi K: Identification and characterization of human thymic cortical dendritic macrophages that may act as professional scavengers of apoptotic thymocytes. Immunobiology 213: 837-47, 2008.

ƒ2007„

Noda C, He J, Takano T, Tanaka C, Kondo T, Tohyama K, Yamamura H, Tohyama Y: Induction of apoptosis by epigallocatechin-3-gallate in human lymphoblastoid B cells. Biochem Biophys Res Comm 362: 951-957, 2007.

Ishikawa T, Tohyama K, Nakao S, et al: A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55-CD59- blood cells predicts platelet response. Int J Hematol 86: 150-157, 2007.

Yang J, Ikezoe T, Nishioka C, Tasaka T, et alFAZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 110: 2034-40, 2007.

Nishioka C, Ikezoe T, Takeshita A, Yang J, Tasaka T, et alFZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244. Leukemia 21: 1308-10, 2007.

Matsuhashi Y, Tasaka T, Kakazu N, et alFEstablishment and characterization of the new splenic marginal zone lymphoma-derived cell line UCH1 carrying a complex rearrangement involving t(8;14) and chromosome 3. Leuk Lymphoma 48: 767-73, 2007.

 

ƒ2006„

Shi Y, Tohyama Y, Kadono T, He J, Shahjahan Miah SM, Hazama R, Tanaka C, Tohyama K, Yamamura H: Protein-tyrosine kinase Syk is required for pathogen engulfment in complement-mediated phagocytosis. Blood 107: 4554-62, 2006.

Tamechika Y, Iwatani Y, Tohyama K, Ichihara K: Insufficient filling of vacuum tubes as a cause of microhemolysis and elevated serum lactate dehydrogenase levels. Use of a data-mining technique in evaluation of questionable laboratory test results. Clin Chem Lab Med 44: 657-61, 2006.

Ikezoe T, Nishioka C, Tasaka T, et al: The antitumor effects of sunitinib(formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.@Mol Cancer Ther 10: 2522-30, 2006.

Tsujioka T, Miura Y, Otsuki T, Nishimura Y, Hyodoh F, Wada H, Sugihara T: The mechanisms of vitamin K2-induced apoptosis of myeloma cells. Haematologica 91: 613-619, 2006.

Miura Y, Tsujioka T, Nishimura Y, Sakaguchi H, Maeda M, Hayashi H, Dong M, Hyodoh F, Yata K, Wada H, Sugihara T, Otsuki T.: TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death. Anticancer Res 26: 4115-4124, 2006.

Kurihara R, Tohyama Y, Matsusaka S, Naruse H, Kinoshita E, Tsujioka T, Katsumata Y, Yamamura H: Effects of peripheral cannabimoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. J Biol Chem 281: 12908-12918, 2006.

 

ƒ2005„

Tohyama K, Shiga S, Itose Y, Uchihashi K, et al: Improved Detection of Minimal Acute Myeloid Leukemia Cells by the Use of the Combined Parameters of XE-2100 Hematology Analyzer. Cytometry B (Clin Cytometry) 66: 18-24, 2005.

He J, Tohyama Y, Yamamoto K, Kobayashi M, Shi Y, Takano T, Noda C, Tohyama K, Yamamura H: Lysosome is a primary organelle in B cell receptor-mediated apoptosis: an indispensable role of Syk in lysosomal function. Genes to Cells@10: 23-35, 2005.

Matsusaka S, Tohyama Y, He J, Shi Y, Hazama R, Kadono T, Kurihara R, Tohyama K, Yamamura H: Protein-tyrosine kinase, Syk, is required for CXCL12-induced polarization of B cells. Biochem Biophys Res Comm 328: 1163-1169, 2005.

 

ƒ2004„

Tasaka T, Matsuhashi Y, Uehara E, Tamura T, Kakazu N, et alF Secondary acute monocytic leukemia with a translocation t(8;16)(p11;p13): case report and review of the literature. Leuk Lymphoma 45: 621-625, 2004.

Matsuhashi Y, Tasaka T, Uehara E, Fujimoto M, Fujita M, et alF Diffuse large B-cell lymphoma presenting with hypercalcemia and multiple osteolysis. Leuk Lymphoma 45: 397-400, 2004.

 

ƒ2003„

Tohyama K, Shiga S, Fujimoto H, Hamaguchi Y, Ichiyama S: Automated analysis of differentiation-induced leukemic cells during all-trans retinoic acid therapy of acute promyelocytic leukemia. Archiv Pathol Lab Med 127: e4-e10, 2003.

Shimamoto T, Tohyama K, Okamoto T, Uchiyama T, et al: Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leukemia Res 27: 783-788, 2003.

Nishihara T, Miura Y, Tohyama Y, Mizutani C, Hishita T, Ichiyama S, Uchiyama T, Tohyama K: Effects of Tyrosine Kinase Inhibitor, Imatinib Messylate on a Bcr-Abl-Positive Cell Line: Suppression of the Autonomous Cell Growth but No Effect on the Decreased Adhesive Property and Morphological Changes. Int J Hematol 78: 233-240, 2003.

Matsuhashi Y, Tasaka T, Uehara E, et al: Increased expression of c-maf in pure red cell aplasia secondary to plasma cell dyscrasia. Leuk Lymphoma 44: 523-524, 2003.

Tsujioka T,Wada H, Yamamori S, Otsuki T, Suemori S, Kondo T, Nakanishi H, Suetsugu Y, Mikami M, Sugihara T.: MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia. Int J Hematol 78(5): 439-442, 2003.

 

ƒ2002„

Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O, Iwakiri R, Hayashi T, Sakamaki H, Murai Y, Tohyama K, Tomoyasu S, Nonaka Y, Mori M, Dan K, Yoshida Y: Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 100: 3887-3896, 2002.

Mizutani C, Tohyama Y, Miura Y, Hishita T, Nishihara T, Yamamura H, Ichiyama S, Uchiyama T, Tohyama K: Sustained activation of MEK1-ERK1/2 pathway in membrane skeleton occurs dependently on cell adhesion in megakaryocytic differentiation. Biochem Biophys Res Comm 297: 664-671, 2002.

Itoh M, Yago K, Shimada H, Tohyama K: Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome. Int J Hematol 75: 302-304, 2002.

Shiga S, Fujimoto H, Mori Y, Sakata T, Hamaguchi Y, Wang F-S, Inomata Y, Tohyama K, Ichiyama S: Immature granulocyte count after liver transplantation. Clin Chem Lab Med 40: 775-780, 2002.